{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:03Z","timestamp":1789535043392,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To describe the diagnostic challenges, treatment response, and potential benefits and risks of cytoreductive surgery in\n                      <jats:italic>de novo<\/jats:italic>\n                      metastatic prostatic small cell neuroendocrine carcinoma (SCNEC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed the clinical course of one patient with\n                      <jats:italic>de novo<\/jats:italic>\n                      metastatic prostatic SCNEC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A 50-year-old man presented in June 2022 with progressive dysuria for more than 1 year and acute urinary retention for 1 day. Transurethral resection of the prostate (TURP) was performed to relieve obstruction, and review of the specimen supported SCNEC. Staging\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT showed an FDG-avid prostate, multiple lymph nodes, and bilateral non-FDG-avid pulmonary nodules without a dominant pulmonary primary; a prostatic primary with clinically suspected pulmonary metastases was favored, although the lung lesions were not biopsied. Seven cycles of etoposide plus cisplatin (EP) produced marked local regression, including a reduction in prostate volume from 72 to 17 cm\u00b3, but residual tumor persisted and a RECIST response category could not be assigned retrospectively. Cytoreductive laparoscopic radical prostatectomy was performed in February 2023. Postoperative pathology showed a mixed neuroendocrine\u2013non-neuroendocrine neoplasm (MiNEN). A vesicourethral anastomotic leak improved conservatively, and urinary obstruction improved for approximately 3 months. Disease progressed in July 2023, and irinotecan plus carboplatin provided no durable clinical disease control. The patient died in December 2023, approximately 18 months after diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EP can produce substantial but temporary regression in metastatic prostatic SCNEC. This case did not establish a survival benefit from surgery, although temporary relief of urinary obstruction was reported. Systemic therapy should remain the priority, and surgery should be limited to carefully selected local-control or palliative indications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1934905","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:28:57Z","timestamp":1789532937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: cytoreductive prostatectomy after platinum\u2013etoposide chemotherapy for de novo metastatic prostatic small cell neuroendocrine carcinoma"],"prefix":"10.3389","volume":"6","author":[{"given":"Yanxin","family":"Wang","sequence":"first","affiliation":[{"name":"Chinese People\u2019s Liberation Army Western Theater General Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwu","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army Western Theater General Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army Western Theater General Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B3","volume-title":"Urinary and Male Genital Tumours","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37427-X","article-title":"Chemotherapy for small cell carcinoma of prostatic origin","volume":"147","author":"Amato","year":"1992","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10523.x","article-title":"Survival of patients with small cell carcinoma of the prostate during 1973\u20132003: a population-based study","volume":"109","author":"Deorah","year":"2012","journal-title":"BJU Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880044","article-title":"Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors","volume":"13","author":"Agoff","year":"2000","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","article-title":"Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases","volume":"32","author":"Wang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.01.002","article-title":"Small-cell carcinoma of the prostate: report of outcomes of localized disease using the National Cancer Database","volume":"19","author":"Xu","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.06.006","article-title":"Metastatic small cell carcinoma of the prostate: population-based analysis of patient characteristics and treatment paradigms","volume":"33","author":"Cohen","year":"2015","journal-title":"Urol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors: what comes next","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1934905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:01Z","timestamp":1789532941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1934905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":13,"alternative-id":["10.3389\/fruro.2026.1934905"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1934905","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1934905"}}